Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally Advanced or metastatic breast cancer
Дата публикации: 09-09-2026 07:09:00

Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
2FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC013.9905-08-2026
3FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting011.6301-06-2026
4FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
5FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer018.0914-07-2026
6FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer018.1416-09-2026
7FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
8U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer020.6624-06-2026
9FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 14.91. Источник: www.esmo.org.